IPO to Apply: Emcure Pharmaceuticals IPO overview! Issue Size, GMP, Issue Price, and All Details to Know {update}

Date:

Share post:

Last updated on June 28th, 2025 at 10:54 pm

Emcure Pharmaceuticals IPO overview! Issue Size, GMP, Issue Price, and All Details to Know Emcure Pharmaceuticals Limited.

About Emcure Pharmaceuticals IPO

Emcure Pharmaceuticals Limited is a vertically integrated pharmaceutical company manufacturing diverse products, including complex injectables, biotherapeutics, and specialty APIs.

Emcure Pharmaceuticals IPO 1

Emcure Pharmaceuticals IPO Details

Emcure Pharmaceuticals Pharmaceutical company

Website: – Click Here

  • Company: Emcure Pharmaceuticals Limited
  • Price Range: ₹960 – ₹1008 per share
  • Total Shares: 13,440 shares
  • Lot Size: 14 shares per lot
  • Start: 3rd July 2024
  • End: 5th July 2024
  • Allotment: 8th July 2024
  • Refund Initiation: 9th July 2024
  • Demat Transfer: 9th July 2024
  • Listing: 10th July 2024
  • Mandate End Date: 20th July 2024
EmployeeClick here
Individual investorClick here

GMP OF Emcure Pharmaceuticals IPO

Emcure Pharmaceuticals IPO GMP is 330 as of today.

[table id=8 /]

Summary of Financial Information

MetricAmount (in ₹ million)Insight
Revenue from Operations66,582.51Total revenue generated from core business operations.
Profit for the Year5,275.75Net profit after accounting for all expenses, taxes, and costs.
Total Borrowings20,919.35All short-term and long-term borrowings.
Net Worth29,522.83Residual interest in assets after deducting liabilities.

Promoters

  1. Satish Ramanlal Mehta
  2. Sunil Rajanikant Mehta
  3. Namita Vikas Thapar
  4. Samit Satish Mehta
PromoterNumber of Equity SharesPercentage of Pre-Offer Equity Share Capital (%)
Satish Ramanlal Mehta75,816,74841.85
Sunil Rajanikant Mehta2,887,0121.59
Namita Vikas Thapar6,339,8003.50
Samit Satish Mehta13,547,6327.48
Total98,591,19254.42

​(Emcure Pharmaceuticals …)

Key Points

  • Competitive Conditions: Emcure operates in a competitive environment and expects competition to intensify.
  • Seasonality: The business is not seasonal in nature.
  • Significant Developments: No significant developments after March 31, 2024, materially affecting operations or profitability have been reported, except the subscription to NCDs issued by Avet Life for ₹2,500.00 million
See also  IXIGO IPO overview! Issue Size, GMP, Issue Price, and All Details to Know

Stock market disclaimer

Note: The information we provide is based on our analysis, do your research before making an investment decision with a stock market disclaimer.

Also Read: – Magenta Lifecare IPO overview! Issue Size, GMP, Issue Price, and All Details to Know.

FAQS Emcure Pharmaceuticals

What is the GMP (Grey Market Premium) of Emcure Pharmaceuticals IPO?

The shares of Emcure Pharmaceuticals IPO are trading at a premium of ₹255 in the grey market premium (GMP).

What is the current share price of Emcure Pharmaceuticals?

As the company is about to list, the current share price in the grey market is at a premium of ₹255 over the issue price band of ₹960 to ₹1008 per share.

When is the Emcure Pharmaceuticals IPO date?

The Emcure Pharmaceuticals IPO opens on July 3, 2024, and closes on July 5, 2024.

What is the Emcure IPO share price?

The price band for the Emcure Pharmaceuticals IPO is set at ₹960 to ₹1008 per share.

What is the GMP (Grey Market Premium) of Emcure Pharmaceuticals IPO?

The GMP for Emcure Pharmaceuticals IPO is ₹255.

What is the valuation of Emcure Pharmaceuticals?

The total IPO size is ₹1952.03 crores, including a fresh issue of ₹800 crores and an offer for sale of ₹1152.03 crores.

When is the Emcure Pharmaceuticals IPO allotment date?

The allotment for Emcure Pharmaceuticals IPO is expected to be finalized on July 8, 2024.

Emcure Pharmaceuticals IPO details in Hindi?

Emcure Pharmaceuticals का IPO 3 जुलाई 2024 को खुलेगा और 5 जुलाई 2024 को बंद होगा। IPO का प्राइस बैंड ₹960 से ₹1008 प्रति शेयर है।

For Advertising, Guest Posting, Newsletter Inserts please contact [email protected]. For general enquiries contact [email protected].

Nikhil Kumar Jha
Nikhil Kumar Jhahttp://moneyphobia.in
I a finance writer with 2+Year of Exp in financial topics. With BBA in Finance degree, content writer, SEBI-certified investor, and stock market enthusiast.

Related articles

Tata Power-DDL Collaborates with Magna Yuma Private Ltd. to establish Battery Swapping Stations in Delhi

Tata Power Delhi Distribution Limited (Tata Power-DDL), a leading power utility supplying electricity to a populace of around...

The Ultimate Guide to Personal Finance on Reddit: Top Communities, Tips, and Insights

Discover the best personal finance communities on Reddit and actionable tips. Learn how to use Reddit discussions to...

NSDL IPO: Big Demand, Grey Market Buzz, and What Experts Are Saying

NSDL has finally hit the market with its much-awaited IPO. The company, which is India’s first and largest...

Citi Brings Back a Premium Card with Strata Elite

Citi has stepped back into the premium credit card market with the launch of the Citi Strata Elite...